DMPH.F Stock Overview
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €42.68 |
| 52 Week High | €42.68 |
| 52 Week Low | €42.68 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how DMPH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DMPH.F performed against the US Market.
Price Volatility
| DMPH.F volatility | |
|---|---|
| DMPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DMPH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,573 | Hans-George Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products.
Dermapharm Holding SE Fundamentals Summary
| DMPH.F fundamental statistics | |
|---|---|
| Market cap | US$2.20b |
| Earnings (TTM) | US$187.27m |
| Revenue (TTM) | US$1.09b |
11.7x
P/E Ratio2.0x
P/S RatioIs DMPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMPH.F income statement (TTM) | |
|---|---|
| Revenue | €1.02b |
| Cost of Revenue | €386.00m |
| Gross Profit | €638.08m |
| Other Expenses | €462.09m |
| Earnings | €175.99m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.27 |
| Gross Margin | 62.31% |
| Net Profit Margin | 17.19% |
| Debt/Equity Ratio | 119.1% |
How did DMPH.F perform over the long term?
See historical performance and comparison